EUVIMEDSkopri EUVIMED
StudienprotokollOpen access

Harm Reduction Contingency Management for Stimulant Use Reduction and Antiretroviral Therapy Adherence in HIV Primary Care: Protocol for an Implementation Effectiveness Study

Gabriela Steiner iD, Stefan Baral iD, Elise D Riley iD, Steven Shoptaw iD, Gabriel Chamie iD, Kate Roberts iD, Lauren Suchman iD, Kelly Knight iD, Monica Gandhi iD, Phillip Coffin iD, Ayesha Appa iD

JMIR Research Protocols · 2025

DOI: 10.2196/67292 ↗

At a glance

Studienprotokoll in JMIR Research Protocols, 2025. Written by Gabriela Steiner and 10 co-authors. Institution: University of California, San Francisco, San Francisco, CA, United States. Major MEDLINE topics: HIV Infections, Medication Adherence, Harm Reduction, Substance-Related Disorders. 42 references. The full text is freely available in PubMed Central. Funded by: NIAMS NIH HHS, NIAID NIH HHS, NIMH NIH HHS.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Stimulant use disorder has been linked with medication nonadherence and mortality among people living with HIV. Contingency management (CM) is a strategy incentivizing measurable behavior change that is recommended as the first-line treatment for stimulant use disorder and can support antiretroviral therapy (ART) adherence. However, CM is not widely implemented, in part due to feasibility concerns. Although reductions in substance use short of full abstinence can improve health outcomes, CM programs typically target complete abstinence from stimulant use rather than reduction. To optimize care for safety-net populations living with comorbid stimulant use disorder and HIV, we designed a novel CM program incentivizing both stimulant use reduction and ART adherence in the HIV ambulatory setting.

Objective

We aimed to (1) evaluate the feasibility of once-weekly CM in safety-net HIV ambulatory care and (2) assess the acceptability of CM among participants and care providers.

Methods

We will conduct a pilot, single-arm, hybrid implementation effectiveness trial offering a novel CM intervention in 2 low-barrier, ambulatory HIV clinics. Patients with stimulant use disorder and suboptimal ART adherence will be offered 12 weeks of once-weekly CM including incentives for positive-tenofovir and negative-stimulant results on urine point-of-care assays. We will assess stimulant use once weekly using tests with a 4-day detection window, allowing participants to use stimulants during select days of the week but earn incentives by reducing their frequency of use from near-daily use. We will assess feasibility and acceptability using quantitative process methods and qualitative in-depth interviews, guided by the RE-AIM (reach, effectiveness, acceptability, implementation, and maintenance) evaluation framework. We will define preliminary effectiveness by proportion of stimulant-negative and tenofovir-positive urine tests, as well as changes in HIV viral suppression before and after participation.

Results

Recruitment and CM visits have concluded as of September 2024. Quantitative and qualitative evaluation is underway and is expected to continue through October 2025.

Conclusions

This novel CM program offers dual incentives targeting stimulant use reduction and ART adherence. We hypothesize that incentivizing stimulant use reduction is acceptable to our target safety-net population. Demonstration of a feasible, acceptable model may serve as a first step toward wider use of stimulant-reduction CM in the safety-net setting. Trial Registration ClinicalTrials.gov NCT06564792; https://clinicaltrials.gov/study/NCT06564792 International Registered Report Identifier (IRRID) DERR1-10.2196/67292

Subjects

MeSH terms (MEDLINE)

HIV InfectionsMedication AdherenceHarm ReductionSubstance-Related DisordersAnti-Retroviral AgentsHumansPrimary Health CarePilot ProjectsMaleCentral Nervous System StimulantsAnti-HIV AgentsFemale

Author keywords

central nervous system stimulantsdrug usersmedication adherencemotivationsubstance use disorder

Substances

Central Nervous System StimulantsAnti-HIV AgentsAnti-Retroviral Agents

Authors and institutions

  • University of California, San Francisco, San Francisco, CA, United States.
  • Johns Hopkins University, Baltimore, MD, United States.
  • University of California, Los Angeles, Los Angeles, CA, United States.
  • Bryn Mawr Graduate School of Social Work and Social Research, Philadelphia, PA, United States.
  • San Francisco Department of Public Health, San Francisco, CA, United States.

ORCID profiles: Gabriela Steiner, Stefan Baral, Elise D Riley, Steven Shoptaw, Gabriel Chamie, Kate Roberts, Lauren Suchman, Kelly Knight, Monica Gandhi, Phillip Coffin, Ayesha Appa

Funding

  • NIAMS NIH HHS
  • NIAID NIH HHS
  • NIMH NIH HHS
  • NIAAA NIH HHS
  • NIDA NIH HHS

Cite

APA

Steiner, G., Baral, S., Riley, E. D., Shoptaw, S., Chamie, G., Roberts, K., Suchman, L., Knight, K., Gandhi, M., Coffin, P., & Appa, A. (2025). Harm Reduction Contingency Management for Stimulant Use Reduction and Antiretroviral Therapy Adherence in HIV Primary Care: Protocol for an Implementation Effectiveness Study. JMIR Research Protocols. https://doi.org/10.2196/67292

Vancouver

Steiner G, Baral S, Riley ED, Shoptaw S, Chamie G, Roberts K, et al. Harm Reduction Contingency Management for Stimulant Use Reduction and Antiretroviral Therapy Adherence in HIV Primary Care: Protocol for an Implementation Effectiveness Study. JMIR Research Protocols. 2025. doi:10.2196/67292

BibTeX
@article{Steiner2025,
  author = {Steiner, Gabriela and Baral, Stefan and Riley, Elise D and Shoptaw, Steven and Chamie, Gabriel and Roberts, Kate and Suchman, Lauren and Knight, Kelly and Gandhi, Monica and Coffin, Phillip and Appa, Ayesha},
  title = {Harm Reduction Contingency Management for Stimulant Use Reduction and Antiretroviral Therapy Adherence in HIV Primary Care: Protocol for an Implementation Effectiveness Study},
  journal = {JMIR Research Protocols},
  year = {2025},
  doi = {10.2196/67292}
}
Start for free →